Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
14156 | 788 | 43.1 | 90% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
171 | 3 | MONASCUS//CITRININ//MONASCUS PURPUREUS | 58457 |
419 | 2 | STATINS//EZETIMIBE//SIMVASTATIN | 16502 |
14156 | 1 | STATINS//SIMVASTATIN//P DIS TB INTERNAL MED | 788 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | STATINS | authKW | 408519 | 35% | 4% | 278 |
2 | SIMVASTATIN | authKW | 106891 | 10% | 4% | 76 |
3 | P DIS TB INTERNAL MED | address | 51664 | 0% | 67% | 2 |
4 | ATORVASTATIN | authKW | 49313 | 6% | 3% | 48 |
5 | INTER PROGRAM IMMUNOL | address | 44025 | 1% | 23% | 5 |
6 | 3 HYDROXI 3 METHYL GLUTARYI COA REDUCTASE INHIBITOR | authKW | 38749 | 0% | 100% | 1 |
7 | 3 HYDROXY 3 METHYGLUTARYL COENZYME A HMG COA REDUCTASE INHIBITORS | authKW | 38749 | 0% | 100% | 1 |
8 | 3 HYDROXY 3 METHYLGLUTARYL COA HMG COA REDUCTASE INHIBITION | authKW | 38749 | 0% | 100% | 1 |
9 | 3 HYDROXY 3 METHYLGLUTARYL REDUCTASE INHIBITORS | authKW | 38749 | 0% | 100% | 1 |
10 | 3 HYDROXY 3 METHYLGUTARYL COENZYME A | authKW | 38749 | 0% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Critical Care Medicine | 1486 | 9% | 0% | 69 |
2 | Immunology | 954 | 18% | 0% | 142 |
3 | Respiratory System | 817 | 9% | 0% | 70 |
4 | Pharmacology & Pharmacy | 622 | 18% | 0% | 145 |
5 | Infectious Diseases | 335 | 7% | 0% | 54 |
6 | Peripheral Vascular Diseases | 265 | 6% | 0% | 48 |
7 | Medicine, Research & Experimental | 212 | 7% | 0% | 57 |
8 | Cardiac & Cardiovascular System | 175 | 7% | 0% | 56 |
9 | Rheumatology | 148 | 3% | 0% | 22 |
10 | Microbiology | 140 | 7% | 0% | 55 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | P DIS TB INTERNAL MED | 51664 | 0% | 67% | 2 |
2 | INTER PROGRAM IMMUNOL | 44025 | 1% | 23% | 5 |
3 | ANESTHESIOL MULTIDISCIPLINARY EPIDEMIOL TR | 38749 | 0% | 100% | 1 |
4 | AREA NEUROCIENCIOS IDIPAZ | 38749 | 0% | 100% | 1 |
5 | ASSOCIATE INTERNAL MED IDENCY PROGRAM | 38749 | 0% | 100% | 1 |
6 | ATHERIOCLEROSIS LIPID DISORDERS | 38749 | 0% | 100% | 1 |
7 | BASIC MED SCI HISTOL EMBRIOL | 38749 | 0% | 100% | 1 |
8 | BHF CARDIOVASC SCI GRP | 38749 | 0% | 100% | 1 |
9 | CECILE VOGT CLIN MOL NEUROL | 38749 | 0% | 100% | 1 |
10 | CELLULAR GENE THER IES HFM725 | 38749 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | SHOCK | 1173 | 1% | 0% | 11 |
2 | INFLAMMOPHARMACOLOGY | 1119 | 0% | 1% | 2 |
3 | INTERNATIONAL IMMUNOPHARMACOLOGY | 1067 | 1% | 0% | 11 |
4 | CRITICAL CARE | 990 | 1% | 0% | 10 |
5 | RESPIRATORY RESEARCH | 771 | 1% | 0% | 6 |
6 | AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY | 662 | 1% | 0% | 10 |
7 | GLIA | 660 | 1% | 0% | 8 |
8 | PULMONARY PHARMACOLOGY & THERAPEUTICS | 647 | 1% | 0% | 5 |
9 | JOURNAL OF LEUKOCYTE BIOLOGY | 540 | 1% | 0% | 10 |
10 | ATHEROSCLEROSIS | 505 | 2% | 0% | 12 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | PAPAZIAN, L , ROCH, A , CHARLES, PE , PENOT-RAGON, C , PERRIN, G , ROULIER, P , GOUTORBE, P , LEFRANT, JY , WIRAMUS, S , JUNG, B , ET AL (2013) EFFECT OF STATIN THERAPY ON MORTALITY IN PATIENTS WITH VENTILATOR-ASSOCIATED PNEUMONIA A RANDOMIZED CLINICAL TRIAL.JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. VOL. 310. ISSUE 16. P. 1692 -1700 | 32 | 73% | 57 |
2 | HENNESSY, E , ADAMS, C , REEN, FJ , O'GARA, F , (2016) IS THERE POTENTIAL FOR REPURPOSING STATINS AS NOVEL ANTIMICROBIALS?.ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. VOL. 60. ISSUE 9. P. 5111 -5121 | 44 | 55% | 2 |
3 | WAN, YD , SUN, TW , KAN, QC , GUAN, FX , ZHANG, SG , (2014) EFFECT OF STATIN THERAPY ON MORTALITY FROM INFECTION AND SEPSIS: A META-ANALYSIS OF RANDOMIZED AND OBSERVATIONAL STUDIES.CRITICAL CARE. VOL. 18. ISSUE 2. P. - | 35 | 71% | 16 |
4 | TROEMAN, DPR , POSTMA, DF , VAN WERKHOVEN, CH , OOSTERHEERT, JJ , (2013) THE IMMUNOMODULATORY EFFECTS OF STATINS IN COMMUNITY-ACQUIRED PNEUMONIA: A SYSTEMATIC REVIEW.JOURNAL OF INFECTION. VOL. 67. ISSUE 2. P. 93-101 | 37 | 76% | 5 |
5 | TRUWIT, JD , BERNARD, GR , STEINGRUB, J , MATTHAY, MA , LIU, KD , ALBERTSON, TE , BROWER, RG , SHANHOLTZ, C , ROCK, P , DOUGLAS, IS , ET AL (2014) ROSUVASTATIN FOR SEPSIS-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME.NEW ENGLAND JOURNAL OF MEDICINE. VOL. 370. ISSUE 23. P. 2191-2200 | 24 | 67% | 80 |
6 | MA, Y , WEN, XZ , PENG, J , LU, Y , GUO, ZM , LU, JH , (2012) SYSTEMATIC REVIEW AND META-ANALYSIS ON THE ASSOCIATION BETWEEN OUTPATIENT STATINS USE AND INFECTIOUS DISEASE-RELATED MORTALITY.PLOS ONE. VOL. 7. ISSUE 12. P. - | 36 | 68% | 15 |
7 | CIURLEO, R , BRAMANTI, P , MARINO, S , (2014) ROLE OF STATINS IN THE TREATMENT OF MULTIPLE SCLEROSIS.PHARMACOLOGICAL RESEARCH. VOL. 87. ISSUE . P. 133 -143 | 42 | 55% | 6 |
8 | TLEYJEH, IM , KASHOUR, T , HAKIM, FA , ZIMMERMAN, VA , ERWIN, PJ , SUTTON, AJ , IBRAHIM, T , (2009) STATINS FOR THE PREVENTION AND TREATMENT OF INFECTIONS A SYSTEMATIC REVIEW AND META-ANALYSIS.ARCHIVES OF INTERNAL MEDICINE. VOL. 169. ISSUE 18. P. 1658 -1667 | 34 | 61% | 127 |
9 | PIHL-JENSEN, G , TSAKIRI, A , FREDERIKSEN, JL , (2015) STATIN TREATMENT IN MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.CNS DRUGS. VOL. 29. ISSUE 4. P. 277 -291 | 32 | 64% | 8 |
10 | TRALHAO, AFR , DE SOUZA-DANTAS, VC , SALLUH, JIF , POVOA, PMSR , (2014) IMPACT OF STATINS IN OUTCOMES OF SEPTIC PATIENTS: A SYSTEMATIC REVIEW.POSTGRADUATE MEDICINE. VOL. 126. ISSUE 7. P. - | 35 | 65% | 4 |
Classes with closest relation at Level 1 |